Berns EM - Search Results

1

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.

Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH. Lammers LA, et al. Among authors: berns em. Br J Cancer. 2010 Sep 7;103(6):765-71. doi: 10.1038/sj.bjc.6605800. Epub 2010 Aug 10. Br J Cancer. 2010. PMID: 20700120 Free PMC article.

2

Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer.

Berns EM, Klijn JG, Smid M, van Staveren IL, Gruis NA, Foekens JA. Berns EM, et al. Br J Cancer. 1995 Oct;72(4):964-7. doi: 10.1038/bjc.1995.442. Br J Cancer. 1995. PMID: 7547249 Free PMC article.

3

Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer.

Berns EM, van Staveren IL, Klijn JG, Foekens JA. Berns EM, et al. Breast Cancer Res Treat. 1998 Mar;48(1):87-92. doi: 10.1023/a:1005903226483. Breast Cancer Res Treat. 1998. PMID: 9541193

4

Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.

Berns EM, van Staveren IL, Look MP, Smid M, Klijn JG, Foekens JA. Berns EM, et al. Br J Cancer. 1998 Apr;77(7):1130-6. doi: 10.1038/bjc.1998.187. Br J Cancer. 1998. PMID: 9569050 Free PMC article.

5

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG. Berns EM, et al. Cancer Res. 2000 Apr 15;60(8):2155-62. Cancer Res. 2000. PMID: 10786679

6

Prognostic significance of germline BRCA2 mutations in hereditary breast cancer patients.

Verhoog LC, Berns EM, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG. Verhoog LC, et al. Among authors: berns em. J Clin Oncol. 2000 Nov 1;18(21 Suppl):119S-24S. J Clin Oncol. 2000. PMID: 11060339 Review.

7

Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.

Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H. Verhoog LC, et al. Eur J Cancer. 2001 Nov;37(16):2082-90. doi: 10.1016/s0959-8049(01)00244-1. Eur J Cancer. 2001. PMID: 11597388

8

Tamoxifen resistance in breast cancer: elucidating mechanisms.

Dorssers LC, Van der Flier S, Brinkman A, van Agthoven T, Veldscholte J, Berns EM, Klijn JG, Beex LV, Foekens JA. Dorssers LC, et al. Among authors: berns em. Drugs. 2001;61(12):1721-33. doi: 10.2165/00003495-200161120-00004. Drugs. 2001. PMID: 11693462 Review.

9

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.

Schuyer M, van der Burg ME, Henzen-Logmans SC, Fieret JH, Klijn JG, Look MP, Foekens JA, Stoter G, Berns EM. Schuyer M, et al. Among authors: berns em. Br J Cancer. 2001 Nov 2;85(9):1359-67. doi: 10.1054/bjoc.2001.2101. Br J Cancer. 2001. PMID: 11720475 Free PMC article.

10

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Bakker B, Sweep FC, Foekens JA. Berns EM, et al. Clin Cancer Res. 2003 Apr;9(4):1253-8. Clin Cancer Res. 2003. PMID: 12684392

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters